Brand names: Prismasol Bgk2/0, Prismasol Bgk2/3.5, Prismasol Bgk4/2.5, Prismasol Bgk0/2.5, Prismasol B22gk4/0, Prismasol Bk0/0/1.2, Prismasol Bgk4/0/1.2, Phoxillum Bk4/2.5, Phoxillum B22k4/0
Route: Intravenous
Contraindications
4 CONTRAINDICATIONS PHOXILLUM and PRISMASOL replacement solutions are contraindicated in patients with known hypersensitivities to these products. Known hypersensitivities to PRISMASOL and PHOXILLUM solutions ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary PRISMASOL and PHOXILLUM are pharmacologically inactive solutions. While there are no adequate and well controlled studies in pregnant women, appropriate administration of PRISMASOL and PHOXILLUM solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm. Animal reproduction studies have not been conducted with PRISMASOL and PHOXILLUM solutions. The estimated background risk of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Maintenance of normal acid-base balance is important for fetal well-being.
1 interaction on record
When used as an anticoagulant, citrate contributes to overall buffer load and can reduce plasma calcium levels. Appropriate PRISMASOL/PHOXILLUM formulation selection is recommended.
Source: NLP:magnesium chloride, dextrose anhydrous, lactic acid, sodium chloride, sodium bicarbonate, and potassium chloride